株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

核医学/放射性医薬品の世界市場予測 2021年:SPECT用放射性医薬品・PET用放射性医薬品・ベータ放射体・アルファ放射体・小線源療法

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

発行 MarketsandMarkets 商品コード 209171
出版日 ページ情報 英文 285 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
核医学/放射性医薬品の世界市場予測 2021年:SPECT用放射性医薬品・PET用放射性医薬品・ベータ放射体・アルファ放射体・小線源療法 Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021
出版日: 2016年10月25日 ページ情報: 英文 285 Pages
概要

核医学/放射性医薬品の市場規模は、今後5年間 (2016-2021年) に9.3%のCAGR (年間複合成長率) で拡大し、2016年の46億7,000万米ドルから2021年までに72億7,000万米ドルへ達すると予測されています。放射性トレーサーの前進と癌・心臓病の発症率・有病率の増加、癌の標的療法向けアルファ放射体の投入、新興市場における放射性医薬品の高い需要、近く発売される放射性同位体、および市場参入企業による新製品発売の増加は、今後の核医学/放射性医薬品市場を促進すると予測されています。しかし、放射性医薬品生産の主要ソースである主な原子炉の閉鎖は、同市場の成長にとって大きな課題となっています。

当レポートは、世界の核医学/放射性医薬品市場について調査分析し、種類、用途、処置数および地域別の市場分析、競合情勢および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 核医学/放射性医薬品:市場概要
  • 地域分析:核医学/放射性医薬品市場、PET用途別
  • 核医学/放射性医薬品市場:種類別
  • 核医学/放射性医薬品市場の地域別スナップショット

第5章 核医学/放射性医薬品の世界市場:概要

  • イントロダクション
  • 市場ダイナミクス
    • 促進因子
    • 阻害因子
    • 機会
    • 課題

第6章 核医学/放射性医薬品の世界市場:種類別

  • イントロダクション
  • 診断用核医学/放射性医薬品
    • SPECT用放射性医薬品
    • PET用放射性医薬品
  • 治療用核医学/放射性医薬品
    • ベータ放射体
    • アルファ放射体
    • 小線源療法

第7章 核医学/放射性医薬品の世界市場:用途別

  • イントロダクション
  • 診断用途
    • SPECT用
    • PET
  • 治療用途用
    • 甲状腺
    • 癌の骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他の治療用途

第8章 核医学/放射性医薬品の世界市場:処置数別

  • イントロダクション
  • 診断用
    • SPECT放射性医薬品
    • PET放射性医薬品
  • 治療用
    • ベータ放射体
    • アルファ放射体
    • 小線源療法同位体

第9章 核医学/放射性医薬品の世界市場:地域別

  • イントロダクション
  • 診断用
    • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • インドにおけるPETスキャナーの設置
    • オーストラリア政府による投資
    • 健康を推進するイニシアチブ
  • その他 (ROW)
    • ラテンアメリカにおけるIAEAのイニシアチブ
    • アルゼンチンの放射線能力の拡大

第10章 核医学/放射性医薬品の世界市場:地域別

  • 治療用核医学/放射性医薬品市場
    • 北米
    • 米国
    • カナダ
    • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州
    • アジア太平洋
    • その他 (RoW)

第11章 競合情勢

  • 概要
  • 市場シェア分析
    • イントロダクション
    • CARDINAL HEALTH, INC. 224
    • MALLINCKRODT PLC 224
    • GE HEALTHCARE 224
    • BAYER HEALTHCARE 225
    • LANTHEUS MEDICAL IMAGING, INC.
  • 競合状況・動向

第12章 企業プロファイル

  • イントロダクション
  • CARDINAL HEALTH, INC.
  • MALLINCKRODT PLC
  • GE HEALTHCARE
  • LANTHEUS MEDICAL IMAGING, INC.
  • BAYER HEALTHCARE
  • BRACCO IMAGING S.P.A
  • ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • NORDION, INC.
  • ADVANCED ACCELERATOR APPLICATIONS S.A.
  • IBA MOLECULAR IMAGING

第13章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PH 3590

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The market is in its growth phase with an increasing number of radioisotope approvals for different clinical indications. Ra-223, I-131, and Y-90 ensured their leading position in the nuclear medicine therapeutic market.

Factors such as advances in radiotracers and increasing incidence and prevalence of cancer and cardiac ailments, introduction of alpha emitters for targeted cancer therapy, high demand for radiopharmaceuticals in emerging markets, upcoming radioisotopes, and increasing new product launches by industry players are expected to drive the nuclear medicine/radiopharmaceuticals market in the coming years. However, the shutdown of major nuclear reactors, which are the main source for radiopharmaceutical production, is a major challenge for the growth of the market.

In 2016, North America is expected to account for the largest share of the global nuclear medicine/radiopharmaceuticals market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate in the forecast period. Factors such as the increasing geriatric population and incidence of cardiovascular diseases & cancer in China & Japan, installation of PET scanners in India, and approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA) in Australia are likely to propel the market in the Asia-Pacific region.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (expansions; new product launches; marketing and promotion; agreements, collaborations, partnerships, and funding; patent approval to increase their market shares and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, sales and marketing directors, other innovation and technology directors, and executives from various key organizations operating in the nuclear medicine/radiopharmaceuticals market

  • By Company Type: Tier 1: 32%, Tier 2: 39%, Tier 3: 29%
  • By Designation: Director Level: 38%, C-level: 28%, Others: 34%
  • By Region: North America: 30%, Europe: 27%, APAC: 33%, RoW: 10%

Some of the major players in the nuclear medicine/radiopharmaceuticals market include Cardinal Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer AG (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).

Research Coverage:

The report provides detailed description of the radiopharmaceuticals used in diagnostics as well as for therapy across various regions. It aims at estimating the market size and future growth potential of this market across different segments such as type, application, procedural volume, and region. Additionally, the report includes an in-depth competitive analysis of the key players in the market along with their company profiles, SWOT analysis, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the products and services offered by top players in the nuclear medicine/radiopharmaceuticals market. The report analyzes the nuclear medicine/radiopharmaceuticals market by type, application, procedural volume, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the nuclear medicine/radiopharmaceuticals market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for nuclear medicine/radiopharmaceuticals across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the nuclear medicine/radiopharmaceuticals market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the nuclear medicine/radiopharmaceuticals market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
    • 2.1.1. RESEARCH DESIGN
    • 2.1.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
      • 2.1.2.1. Secondary research
      • 2.1.2.2. Primary research
      • 2.1.2.3. Key industry insights
    • 2.1.3. KEY DATA FROM PRIMARY SOURCES
    • 2.1.4. KEY INSIGHTS FROM PRIMARY SOURCES
    • 2.1.5. MARKET SIZE ESTIMATION METHODOLOGY
    • 2.1.6. MARKET DATA VALIDATION AND TRIANGULATION
    • 2.1.7. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PET APPLICATION (2016)
  • 4.3. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2016 VS. 2021)
  • 4.4. GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Investments through public-private partnerships to modernize diagnostic imaging centers
      • 5.2.1.2. Alpha radioimmunotherapy-based targeted cancer treatment
      • 5.2.1.3. Advances in radiotracers
      • 5.2.1.4. Increasing incidence and prevalence of cancer and cardiac ailments
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Shorter half-life of radiopharmaceuticals
      • 5.2.2.2. High cost of nuclear medicine equipment
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. High demand in emerging markets
      • 5.2.3.2. Upcoming radioisotopes
      • 5.2.3.3. Use of radiopharmaceuticals in neurological applications
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Shutdown of nuclear reactors

6. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
    • 6.2.1. SPECT RADIOPHARMACEUTICALS
      • 6.2.1.1. Technetium-99m
      • 6.2.1.2. Thallium-201
      • 6.2.1.3. Gallium-67
      • 6.2.1.4. Iodine-123
      • 6.2.1.5. Other spect isotopes
    • 6.2.2. PET RADIOPHARMACEUTICALS
      • 6.2.2.1. Fluorine-18
      • 6.2.2.2. Rubidium-82
      • 6.2.2.3. Other pet isotopes
  • 6.3. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
    • 6.3.1. BETA EMITTERS
      • 6.3.1.1. Iodine-131
      • 6.3.1.2. Yttrium-90
      • 6.3.1.3. Samarium-153
      • 6.3.1.4. Rhenium-186
      • 6.3.1.5. Lutetium-177
      • 6.3.1.6. Other beta emitters
    • 6.3.2. ALPHA EMITTERS
      • 6.3.2.1. Radium-223
    • 6.3.3. BRACHYTHERAPY ISOTOPES
      • 6.3.3.1. Iodine-125
      • 6.3.3.2. Iridium-192
      • 6.3.3.3. Palladium-103
      • 6.3.3.4. Cesium-131
      • 6.3.3.5. Other brachytherapy isotopes

7. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 7.1. INTRODUCTION
  • 7.2. DIAGNOSTIC APPLICATIONS
    • 7.2.1. SPECT APPLICATIONS
      • 7.2.1.1. Cardiology
      • 7.2.1.2. Neurology
      • 7.2.1.3. Thyroid
      • 7.2.1.4. Other spect applications
    • 7.2.2. PET APPLICATIONS
      • 7.2.2.1. Oncology
      • 7.2.2.2. Cardiology
      • 7.2.2.3. Neurology
      • 7.2.2.4. Other pet applications
  • 7.3. THERAPEUTIC APPLICATIONS
    • 7.3.1. THYROID
    • 7.3.2. BONE METASTASIS
    • 7.3.3. LYMPHOMA
    • 7.3.4. ENDOCRINE TUMORS
    • 7.3.5. OTHER THERAPEUTIC APPLICATIONS

8. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

  • 8.1. INTRODUCTION
  • 8.2. DIAGNOSTIC PROCEDURES
    • 8.2.1. SPECT RADIOPHARMACEUTICALS
    • 8.2.2. PET RADIOPHARMACEUTICALS
  • 8.3. THERAPEUTIC PROCEDURES
    • 8.3.1. BETA EMITTERS
    • 8.3.2. ALPHA EMITTERS
    • 8.3.3. BRACHYTHERAPY ISOTOPES

9. GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. DIAGNOSTICS
    • 9.2.1. NORTH AMERICA
    • 9.2.2. U.S.
      • 9.2.2.1. Domestic production of mo-99 in the U.S.
      • 9.2.2.2. Approval of new radiopharmaceuticals by the FDA
    • 9.2.3. CANADA
      • 9.2.3.1. Extension of operations at the canadian national research universal (NRU) reactor
      • 9.2.3.2. Alternative medical isotope technologies in CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
      • 9.3.1.1. New irradiation facility in GERMANY
    • 9.3.2. FRANCE
      • 9.3.2.1. Shutdown of the french osiris nuclear reactor
    • 9.3.3. U.K.
      • 9.3.3.1. Increasing adoption of nuclear medicine equipment
    • 9.3.4. ITALY
      • 9.3.4.1. Steady growth in healthcare expenditure
    • 9.3.5. SPAIN
      • 9.3.5.1. Role of the semnim in SPAIN
    • 9.3.6. REST OF EUROPE (ROE)
      • 9.3.6.1. Rapid rise in the geriatric population
  • 9.4. ASIA-PACIFIC
    • 9.4.1. INSTALLATIONS OF PET SCANNERS IN INDIA
    • 9.4.2. INVESTMENTS BY THE AUSTRALIAN GOVERNMENT
    • 9.4.3. INITIATIVES TO PROMOTE HEALTH
  • 9.5. REST OF THE WORLD
    • 9.5.1. IAEA INITIATIVES IN LATAM
    • 9.5.2. ARGENTINA'S INCREASING IRRADIATION CAPACITY

10. GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION

  • 10.1. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    • 10.1.1. NORTH AMERICA
    • 10.1.2. U.S.
      • 10.1.2.1. FDA approval for alpha emitters
      • 10.1.2.2. Therapeutic nuclear medicine - alternative treatment choice in oncology
    • 10.1.3. CANADA
      • 10.1.3.1. Expertise in isotope production
      • 10.1.3.2. Government initiatives to increase the number of nuclear medicine treatment centers
    • 10.1.4. EUROPE
    • 10.1.5. GERMANY
      • 10.1.5.1. Radionuklidtherapeutika - a research program conducted in GERMANY
    • 10.1.6. FRANCE
      • 10.1.6.1. The firm project
    • 10.1.7. U.K.
      • 10.1.7.1. "A voice for radiotherapy" initiative in the U.K.
    • 10.1.8. ITALY
      • 10.1.8.1. Growing incidences of cancer
    • 10.1.9. SPAIN
      • 10.1.9.1. Rising demand for radiotherapeutics
    • 10.1.10. ROE
      • 10.1.10.1. Government and public-private investments
      • 10.1.10.2. Research on cancer in POLAND
    • 10.1.11. ASIA-PACIFIC
      • 10.1.11.1. Increasing aging population in JAPAN
      • 10.1.11.2. Aging population and increasing cancer prevalence in CHINA
      • 10.1.11.3. Approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA) in AUSTRALIA
    • 10.1.12. REST OF THE WORLD (ROW)
      • 10.1.12.1. Increase in cancer incidences

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
    • 11.2.1. INTRODUCTION
    • 11.2.2. CARDINAL HEALTH, INC.
    • 11.2.3. MALLINCKRODT PLC
    • 11.2.4. GE HEALTHCARE
    • 11.2.5. BAYER HEALTHCARE
    • 11.2.6. LANTHEUS MEDICAL IMAGING, INC.
  • 11.3. COMPETITIVE SITUATIONS AND TRENDS
    • 11.3.1. AGREEMENTS, PARTNERSHIPS, AND CONTRACTS
    • 11.3.2. MARKETING AND PROMOTIONAL ACTIVITIES
    • 11.3.3. EXPANSIONS
    • 11.3.4. ACQUISITIONS
    • 11.3.5. PRODUCT APPROVALS
    • 11.3.6. DIVESTMENTS
    • 11.3.7. PRODUCT LAUNCHES
    • 11.3.8. OTHER STRATEGIES

12. COMPANY PROFILES (Overview, Products and Services, Financials, Strategy & Development)*

  • 12.1. INTRODUCTION
  • 12.2. CARDINAL HEALTH, INC.
  • 12.3. MALLINCKRODT PLC
  • 12.4. GE HEALTHCARE (A FULLY OWNED SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
  • 12.5. LANTHEUS MEDICAL IMAGING, INC.
  • 12.6. BAYER AG
  • 12.7. BRACCO IMAGING S.P.A
  • 12.8. ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • 12.9. NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL LLC.)
  • 12.10. ADVANCED ACCELERATOR APPLICATIONS S.A.
  • 12.11. IBA MOLECULAR

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. OTHER DEVELOPMENTS
    • 13.3.1. CARDINAL HEALTH, INC.
    • 13.3.2. MALLINCKRODT PLC
    • 13.3.3. GE HEALTHCARE
    • 13.3.4. LANTHEUS MEDICAL IMAGING, INC.
    • 13.3.5. BAYER AG
    • 13.3.6. BRACCO IMAGING S.P.A
    • 13.3.7. ECZACIBASI-MONROL NUCLEAR PRODUCTS
    • 13.3.8. NORDION, INC.
    • 13.3.9. ADVANCED ACCELERATOR APPLICATIONS S.A.
    • 13.3.10. IBA MOLECULAR
  • 13.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.6. AVAILABLE CUSTOMIZATIONS
  • 13.7. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 2: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 3: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 5: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 6: SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 7: SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 9: EUROPE: SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 10: TECHNETIUM-99M MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: NORTH AMERICA: TECHNETIUM-99M NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 12: EUROPE: TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 13: THALLIUM-201 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: NORTH AMERICA: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 15: EUROPE: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 16: GALLIUM-67 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: NORTH AMERICA: GALLIUM-67 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 18: EUROPE: GALLIUM-67 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 19: IODINE-123 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: NORTH AMERICA: IODINE-123 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 21: EUROPE: IODINE-123 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 22: OTHER SPECT ISOTOPES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: NORTH AMERICA: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 24: EUROPE: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 25: PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 26: PET RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 28: EUROPE: PET RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 29: FLUORINE-18 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: NORTH AMERICA: FLUORINE-18 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 31: EUROPE: FLUORINE-18 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 32: RUBIDIUM-82 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 33: NORTH AMERICA: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 34: EUROPE: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 35: OTHER PET ISOTOPES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 36: NORTH AMERICA: OTHER PET ISOTOPES NUCLEAR MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 37: EUROPE: OTHER PET ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 38: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 39: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 40: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 41: EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 42: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 43: BETA EMITTERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 44: NORTH AMERICA: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 45: EUROPE: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 46: IODINE-131 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 47: NORTH AMERICA: IODINE-131 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 48: EUROPE: IODINE 131 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 49: YTTRIUM-90 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 50: NORTH AMERICA: YTTRIUM-90 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 51: EUROPE: YTTRIUM-90 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 52: SAMARIUM-153 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 53: NORTH AMERICA: SAMARIUM-153 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 54: EUROPE: SAMARIUM-153 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 55: RHENIUM-186 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 56: NORTH AMERICA: RHENIUM-186 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 57: EUROPE: RHENIUM-186 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 58: LUTETIUM-177 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 59: NORTH AMERICA: LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 60: EUROPE: LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 61: OTHER BETA EMITTERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 62: NORTH AMERICA: OTHER BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 63: EUROPE: OTHER BETA EMITTERS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 64: RADIUM-223 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 65: NORTH AMERICA: RADIUM-223 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 66: EUROPE: RADIUM-223 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 67: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 68: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 69: NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 70: EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 71: IODINE-125 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 72: NORTH AMERICA: IODINE-125 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 73: EUROPE: IODINE-125 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 74: IRIDIUM-192 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 75: NORTH AMERICA: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 76: EUROPE: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 77: PALLADIUM-103 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 78: NORTH AMERICA: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 79: EUROPE: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 80: CESIUM-131 MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 81: NORTH AMERICA: CESIUM-131 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 82: EUROPE: CESIUM-131 MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 83: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 84: NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 85: EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 86: SPECT APPLICATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 87: SPECT APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 88: NORTH AMERICA: SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 89: EUROPE: SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 90: CARDIOLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 91: NORTH AMERICA: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 92: EUROPE: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 93: NEUROLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 94: NORTH AMERICA: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 95: EUROPE: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 96: THYROID APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 97: NORTH AMERICA: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 98: EUROPE: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 99: OTHER SPECT APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 100: NORTH AMERICA: OTHER SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 101: EUROPE: OTHER SPECT APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 102: PET APPLICATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 103: PET APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 104: NORTH AMERICA: PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 105: EUROPE: PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 106: ONCOLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 107: NORTH AMERICA: ONCOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 108: EUROPE: ONCOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 109: CARDIOLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 110: NORTH AMERICA: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 111: EUROPE: CARDIOLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 112: NEUROLOGY APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 113: NORTH AMERICA: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 114: EUROPE: NEUROLOGY APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 115: OTHER PET APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 116: NORTH AMERICA: OTHER PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 117: EUROPE: OTHER PET APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 118: THERAPEUTIC APPLICATIONS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 119: THYROID APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 120: NORTH AMERICA: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 121: EUROPE: THYROID APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 122: BONE METASTASIS APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 123: NORTH AMERICA: BONE METASTASIS APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 124: EUROPE: BONE METASTASIS APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 125: LYMPHOMA APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 126: NORTH AMERICA: LYMPHOMA APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 127: EUROPE: LYMPHOMA APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 128: ENDOCRINE TUMOR APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 129: NORTH AMERICA: ENDOCRINE TUMOR APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 130: EUROPE: ENDOCRINE TUMOR APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 131: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 132: NORTH AMERICA: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 133: EUROPE: OTHER THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 134: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME, 2014-2021 (THOUSAND UNITS)
  • TABLE 135: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (THOUSAND UNITS)
  • TABLE 136: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (THOUSAND UNITS)
  • TABLE 137: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (THOUSAND UNITS)
  • TABLE 138: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (THOUSAND UNITS)
  • TABLE 139: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (THOUSAND UNITS)
  • TABLE 140: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (THOUSAND UNITS)
  • TABLE 141: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (THOUSAND UNITS)
  • TABLE 142: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (THOUSAND UNITS)
  • TABLE 143: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (THOUSAND UNITS)
  • TABLE 144: BETA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (THOUSAND UNITS)
  • TABLE 145: BETA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (THOUSAND UNITS)
  • TABLE 146: ALPHA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (THOUSAND UNITS)
  • TABLE 147: BRACHYTHERAPY ISOTOPES NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (THOUSAND UNITS)
  • TABLE 148: BRACHYTHERAPY ISOTOPES NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (THOUSAND UNITS)
  • TABLE 149: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 150: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 151: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 152: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 153: NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 154: NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 155: NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 156: NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 157: U.S.: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 158: U.S.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 159: U.S.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 160: U.S.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 161: U.S.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 162: CANADA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 163: CANADA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 164: CANADA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 165: CANADA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 166: CANADA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 167: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 168: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 169: EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 170: EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 171: EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 172: EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 173: GERMANY: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 174: GERMANY: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 175: GERMANY: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 176: GERMANY: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 177: GERMANY: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 178: FRANCE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 179: FRANCE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 180: FRANCE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 181: FRANCE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 182: FRANCE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 183: U.K.: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 184: U.K.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 185: U.K.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 186: U.K.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 187: U.K.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 188: ITALY: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 189: ITALY: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 190: ITALY: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 191: ITALY: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 192: ITALY: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 193: SPAIN: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 194: SPAIN: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 195: SPAIN: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 196: SPAIN: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 197: SPAIN: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 198: ROE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 199: ROE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 200: ROE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 201: ROE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 202: ROE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 203: ASIA-PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 204: ASIA-PACIFIC: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 205: ASIA-PACIFIC: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 206: ASIA-PACIFIC: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 207: ASIA-PACIFIC: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 208: ROW: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 209: ROW: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 210: ROW: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 211: ROW: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 212: ROW: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 213: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 214: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 215: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 216: NORTH AMERICA: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 217: NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 218: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 219: U.S.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 220: U.S.: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 221: U.S.: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 222: U.S.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 223: CANADA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 224: CANADA: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 225: CANADA: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 226: CANADA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 227: EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 228: EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 229: EUROPE: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 230: EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 231: EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 232: GERMANY: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 233: GERMANY: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 234: GERMANY: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 235: GERMANY: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 236: FRANCE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 237: FRANCE: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 238: FRANCE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 239: FRANCE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 240: U.K.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 241: U.K.: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 242: U.K.: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 243: U.K.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 244: ITALY: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 245: ITALY: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 246: ITALY: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 247: ITALY: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 248: SPAIN: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 249: SPAIN: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 250: SPAIN: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 251: SPAIN: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 252: ROE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 253: ROE: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 254: ROE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 255: ROE:: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 256: ASIA-PACIFIC: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 257: ASIA-PACIFIC: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 258: ASIA-PACIFIC: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 259: ASIA-PACIFIC: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 260: ROW: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 261: ROW: BETA EMITTERS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 262: ROW: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 263: ROW: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 264: AGREEMENTS, PARTNERSHIPS, AND CONTRACTS (2013-2016)
  • TABLE 265: MARKETING AND PROMOTIONAL ACTIVITIES (2013-2016)
  • TABLE 266: EXPANSIONS (2013-2016)
  • TABLE 267: ACQUISITIONS (2013-2016)
  • TABLE 268: PRODUCT APPROVALS (2013-2016)
  • TABLE 269: DIVESTMENTS (2013-2016)
  • TABLE 270: PRODUCT LAUNCHES (2013-2016)
  • TABLE 271: OTHER STRATEGIES (2013-2016)

LIST OF FIGURES

  • FIGURE 1: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION
  • FIGURE 2: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 3: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET ANALYSIS, BY TYPE (2016 VS. 2021)
  • FIGURE 8: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC APPLICATIONS MARKET SIZE, BY SPECT TECHNIQUE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 10: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET PROJECTED TO WITNESS A HIGH GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 11: ONCOLOGY SEGMENT TO DOMINATE THE PET APPLICATIONS MARKET IN 2016
  • FIGURE 12: DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS IN 2021
  • FIGURE 13: APAC TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 14: NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 15: DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET IN 2016
  • FIGURE 16: PET SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 17: ALPHA EMITTERS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 18: NEUROLOGY APPLICATIONS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 19: NEUROLOGY APPLICATIONS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 20: ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 21: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME (2016 VS. 2021)
  • FIGURE 22: NORTH AMERICA TO DOMINATE THE DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET IN 2016
  • FIGURE 23: NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 24: EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 25: ASIA-PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 26: ROW DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 27: NORTH AMERICA TO DOMINATE THE THERAPEUTIC NUCLEAR MEDICINE /RADIOPHARMACEUTICALS MARKET IN 2016
  • FIGURE 28: NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 29: EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 30: ASIA-PACIFIC THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 31: ROW THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SNAPSHOT
  • FIGURE 32: AGGREEMENTS, PARTNERSHIPS, AND CONTRACTS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS BETWEEN 2013 & 2016
  • FIGURE 33: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER (2015)
  • FIGURE 34: AGREEMENTS, PARTNERSHIPS, AND CONTRACTS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
  • FIGURE 35: AGREEMENTS, PARTNERSHIPS, AND CONTRACTS, BY COMPANY (2013-2016)
  • FIGURE 36: MARKETING AND PROMOTIONAL ACTIVITIES, BY COMPANY (2013-2016)
  • FIGURE 37: EXPANSIONS, BY COMPANY (2013-2016)
  • FIGURE 38: ACQUISITIONS, BY COMPANY (2013-2016)
  • FIGURE 39: PRODUCT APPROVALS, BY COMPANY (2013-2016)
  • FIGURE 40: DIVESTMENTS, BY COMPANY (2013-2016)
  • FIGURE 41: PRODUCT LAUNCHES, BY COMPANY (2013-2016)
  • FIGURE 42: OTHER STRATEGIES, BY COMPANY (2013-2016)
  • FIGURE 43: GEOGRAPHIC REVENUE MIX OF THE PROMINENT PLAYERS (2015)
  • FIGURE 44: CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
  • FIGURE 45: MALLINCKRODT PLC: COMPANY SNAPSHOT
  • FIGURE 46: GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 47: LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT
  • FIGURE 48: BAYER AG: COMPANY SNAPSHOT
  • FIGURE 49: ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
Back to Top